Comparative Pharmacology
Head-to-head clinical analysis: HALCION versus PRAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALCION versus PRAZEPAM.
HALCION vs PRAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
Prazepam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
10-30 mg orally 3-4 times daily; maximum daily dose 60 mg.
None Documented
None Documented
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Clinical Note
moderatePrazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate."
Clinical Note
moderatePrazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Cyclosporine
Terminal elimination half-life: 36-200 hours (mean ~75 hours). Long half-life leads to accumulation with repeated dosing and prolonged sedation, especially in elderly or hepatic impairment.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Primarily renal (as conjugated metabolites, mainly oxazepam glucuronide): ~95%; fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Prazepam."